Overview

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis

Status:
Not yet recruiting
Trial end date:
2022-07-10
Target enrollment:
Participant gender:
Summary
Randomized, double blind, placebo controlled study. The study has two parts: Dose-finding part, followed by longer term follow-up (6 months)
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
AlgiPharma AS
Collaborators:
Cystic Fibrosis Europe
Cystic Fibrosis Foundation
European Cystic Fibrosis Society
Imperial College London
University Hospital of Cologne